How new medicines get approved and finally reach patients today

In the last two weeks of October 2026, regulators in the US and the UK approved a cluster of new treatments: a hepatitis B medicine that lets some people stop treatment, a once-weekly insulin, a daily pill for psoriasis, a gene-editing therapy for younger children, and a DNA immunotherapy for a rare airway disease. Each announcement raised the same questions from readers. Does approved mean I can have it? Why is it available in one country and not another? What does accelerated approval mean?

This guide explains the steps between a successful trial and a medicine reaching patients, with a focus on the US and the UK, and uses those five recent decisions as examples.

This guide is for general information and is not medical advice. Please speak to your own doctor or pharmacist about any medicine.

From trial to application

A medicine usually reaches a regulator after three phases of human trials. Phase 1 tests safety and dosing in small groups. Phase 2 looks for signs that it works and refines the dose. Phase 3 compares it with placebo or an existing treatment in hundreds or thousands of people.

The company then puts together a marketing application: the full trial data, manufacturing details, proposed labelling and a plan for monitoring safety. In the US this is a New Drug Application or Biologics License Application to the Food and Drug Administration (FDA). In the UK it goes to the Medicines and Healthcare products Regulatory Agency (MHRA). In the EU it usually goes to the European Medicines Agency (EMA), whose committee gives an opinion before the European Commission makes the legal decision.

Each regulator makes its own decision. A yes in one country does not bind any other.

What regulators judge

Regulators ask three core questions:

• Does the medicine work for the proposed use?
• Are its benefits greater than its risks for the people it is meant for?
• Can it be made consistently to a high standard?

They do not usually ask whether it is good value for money. In the UK, that is a separate job for the National Institute for Health and Care Excellence (NICE) in England and its counterparts in Scotland, Wales and Northern Ireland.

How long a review takes

The FDA aims to review standard applications within about 10 months of accepting them and priority applications within about six months. The MHRA's national route has a 150-day assessment timetable, and it also has an International Recognition Procedure that can rely on decisions by trusted regulators such as the FDA or EMA. The EMA's standard scientific assessment currently allows up to 210 active days, and the EU pharma package adopted by the Council in September 2026 would cut that to 180, as we report in our article on the EU pharma package.

Timelines can stop and start while companies answer questions, so real-world reviews often take longer.

Standard approval and its variations

Most medicines get a standard approval based on phase 3 trials that measured an outcome patients care about directly. The UK approval of Onswik, a once-weekly insulin, rested on the QWINT trials, in which it lowered blood sugar about as well as daily insulin. The Icotyde psoriasis pill was approved by the MHRA after trials in which it beat placebo and an existing oral psoriasis drug. The FDA's approval of Hibsago for chronic hepatitis B was based on two phase 3 trials and carries a boxed warning, the FDA's strongest safety label.

A licence can also be widened later. The MHRA's decision to extend Casgevy to children aged five and over is a change to an existing approval, based on data in younger patients.

Accelerated and conditional approval

For serious conditions with few options, regulators have faster routes that accept earlier or less complete evidence.

In the US, accelerated approval lets the FDA approve a medicine based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict a real clinical benefit. The company must then run confirmatory trials. If they fail to confirm the benefit, the FDA can withdraw the approval.

The FDA's accelerated approval of Voceryq for recurrent respiratory papillomatosis is a current example. It rests on a single open-label trial of 32 adults, using the need for repeat surgery as the endpoint, and the maker must run a confirmatory trial.

The UK and EU have a comparable tool, conditional marketing authorisation, which is renewed annually while more data are gathered.

These routes get medicines to patients sooner. The trade-off is more uncertainty at the moment of approval, which patients should know about when they discuss treatment.

Special designations

You will often see extra labels on a medicine:

• Orphan designation, for rare diseases, which brings incentives such as fee reductions and a period of market exclusivity.
• Breakthrough therapy and fast track in the US, which mean more FDA support during development.
• Priority review in the US, which shortens the review clock.
• The Innovation Passport under the UK's Innovative Licensing and Access Pathway, which brings agencies together earlier.

A designation signals that a regulator sees promise. It is not an approval.

After approval, who pays

In the US, approval allows a medicine to be sold, but access depends on insurers, pharmacy benefit managers and government programmes deciding to cover it, and on the price to the patient.

In the UK, an MHRA licence is the first step. For the NHS in England to fund a new medicine routinely, NICE usually needs to recommend it through a technology appraisal. NICE weighs clinical benefit against cost. When NICE recommends a medicine, the NHS in England normally has to make it available within three months of final guidance.

The October 2026 decisions show the different stages:

• Onswik was licensed by the MHRA on 13 October and recommended by NICE on 16 October, so NHS funding should follow within 90 days.
• Icotyde was licensed by the MHRA on 23 October, but NICE was still appraising it, so routine NHS access was not yet in place.
• For Casgevy, NICE updated its guidance on the same day the extension was announced, so children could be treated through the existing managed access arrangement.
• Hibsago was approved in the US only. It was under EMA review, with no MHRA decision, so it was not available in the UK or EU at the time of approval.

Scotland, Wales and Northern Ireland have their own arrangements, through the Scottish Medicines Consortium and the All Wales Medicines Strategy Group, with Northern Ireland usually following NICE.

Why a medicine is approved in one country and not another

Several things explain the gaps:

• The company may have applied in one country first, or not yet applied elsewhere.
• Regulators can reach different judgements on the same data, especially when evidence is limited.
• Review timetables differ.
• Pricing and reimbursement decisions can delay launch even after approval.

Safety monitoring never stops

Approval is a point in time. Once a medicine is in wide use, rare side effects can appear that trials were too small to detect. Regulators monitor reports and can update labels, add warnings or restrict use.

In the UK, anyone can report a suspected side effect through the MHRA's Yellow Card scheme. In the US, the FDA's MedWatch programme does the same. Reports from patients are valued, and you do not need to be certain the medicine caused the problem to report it.

Reading the label and leaflet

Every approved medicine comes with official product information. In the UK this is the Summary of Product Characteristics for prescribers and the patient information leaflet in the pack. In the US it is the prescribing information, sometimes with a medication guide for patients. These documents set out exactly who the medicine is licensed for, the dose, the known side effects and any warnings. If a news story and the leaflet seem to disagree, the leaflet reflects what the regulator actually approved. You can find UK documents on the electronic medicines compendium and US labels on the FDA's Drugs@FDA database.

Early access before approval

Sometimes patients can get a medicine before it is licensed, through a clinical trial, an early access programme, or individual named-patient use. In the UK, the Early Access to Medicines Scheme allows use of promising medicines for serious conditions before a licence. Our guide on how to find and join a clinical trial explains how to look for studies.

Questions to ask about a newly approved medicine

• Is it approved in my country, and for someone with my condition and age?
• Is it funded by my health service or insurer?
• What did the trials compare it with, and how big was the benefit in absolute terms?
• Was it approved through a fast route, and what is still uncertain?
• What are the main side effects, and is there a boxed warning?

Our guide on how to read clinical trial results can help with the third question.

Approval is a major step, and for many people the more important milestone is when their own health service decides to pay. Knowing which stage a medicine has reached makes news about it easier to read and helps you have a clearer conversation with your doctor.

Related reading

• FDA approves Hibsago for chronic hepatitis B
• Onswik once-weekly insulin approved in the UK
• UK extends Casgevy to children aged five and over
• MHRA Strategy 2030 sets new targets for approvals